HOXC6 gene silencing inhibits epithelial-mesenchymal transition and cell viability through the TGF-β/smad signaling pathway in cervical carcinoma cells

Feng Zhang¹, Chen-Chen Ren¹, Ling Liu¹, Yan-Nan Chen¹, Li Yang¹* and Xiao-An Zhang²*

Abstract

Background: Homeobox C6 (HOXC6) plays a part in malignant progression of some tumors. However, the expression of HOXC6 and its clinical significance remains unclear in cervical carcinoma (CC). The purpose of this study is to verify the effects of HOXC6 gene silencing on CC through the TGF-β/smad signaling pathway.

Methods: CC tissues and corresponding paracancerous tissues were collected from CC patients with involvement of a series of HOXC6-siRNA, HA-HOXC6 and the TGF-β/smad pathway antagonist. HOXC6 expression was analyzed in six CC cell lines (C-33A, HeLa, CaSkI, SiHa, ME-180, and HCC-94) by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analysis. The mRNA and protein expression of HOXC6, TGF-β1, TGF-β RII, smad4, smad7, E-cadherin, N-cadherin, Vimentin, ki-67, proliferating cell nuclear antigen (PCNA), p27, and Cyclin D1 were determined by RT-qPCR and western blot analysis. Cell proliferation, apoptosis and cell cycle were detected by MTT assay and flow cytometry, respectively.

Results: Higher positive expression rate of HOXC6 protein was observed in CC tissues and HOXC6 was related to TNM stage, lymphatic metastasis, cancer types, primary lesion diameter, and histological grade of CC. Silencing HOXC6 inhibited epithelial-mesenchymal transition (EMT) (shown as decreased N-cadherin and Vimentin, and increased E-cadherin) through the inactivation of the TGF-β/smad signaling pathway. HOXC6 gene silencing hindered cell proliferation and accelerated cell apoptosis of CC cells. Furthermore, the effect of HOXC6 silencing was enhanced when the TGF-β/smad signaling pathway was suppressed.

Conclusion: The results reveal that HOXC6 gene silencing may inhibit EMT event and cell viability in CC through the inhibition of the activation of TGF-β/smad signaling pathway.

Keywords: HOXC6, TGF-β/smad signaling pathway, Epithelial-mesenchymal transition, Cervical carcinoma, Cell viability
Background
Cervical carcinoma (CC) remains the second commonest female cancer across the world and prevalently occurs in many low-income countries, mainly caused by persistent infection with human papilloma virus [1]. Except high incidence, CC is ranked as the 4th most common cancer-related death among women, with 88% of all deaths in developing countries [2]. Additionally, the main symptoms of CC include post-coital vaginal bleeding, postmenopausal vaginal bleeding, intermenstrual vaginal bleeding, lower abdominal pain and offensive vaginal discharge [3]. As a low-cost and simple alternative to traditional Pap smears, visual inspection with acetic acid has been widely used for CC diagnosis, whose advantage is that women can be screened and treated at the same time [4]. Although the diagnostic and therapeutic strategies get improved continuously, the 5-year survival rate for advanced CC patients is still poor [5]. Hence, researches on the potential molecular mechanisms underlying CC progression are urgently needed for effective treatment modalities for CC patients.

Homeobox (HOX) genes, as a family of transcription factors, are responsible for the regulation of gene expression by directly binding to specific DNA sequences of target genes [6]. It has been reported that HOX gene takes part in leukemogenic transformation and is highly expressed in hematologic malignancies [7]. Recent evidence suggests that homeobox C6 (HOXC6) gene, a critical player in milk production and mammary gland development, has been found to be overexpressed in medulloblastomas [8] and osteosarcomas [9], as well as in variety of carcinomas including breast [10], lung [11] and prostate cancers [12]. A recent study has demonstrated that HOXC6 can exert diagnostic value in early detection and has monitoring function on progression or response to therapy, thus serving as a novel biomarker for prostatic cancer [13]. In addition, HOX proteins are reported to interact with Smads [14]. Smads, as multifunctional proteins, can promote the expression of multiple microRNAs by advancing the cleavage reaction and act as the signal transducers in TGF-β/bone morphogenetic protein pathway [15]. Transforming growth factor-β (TGF-β) signaling pathway plays an essential role in many development processes in human and animals [16], and it has been confirmed as a critical modulator for many cellular processes correlated with carcinogenesis [17]. It has reported that the TGF-β/smads pathway was activated in cervical squamous carcinoma [18]. Based on the above, HOXC6 may play a critical role in CC by binding to the TGF-β/smads signaling pathway. Thus, this study aims to evaluate the mechanism of HOXC6 in relation to the TGF-β/smads signaling pathway in CC. Furthermore, the study defined the hypothesis that HOXC6 gene silencing inhibits epithelial-mesenchymal transition (EMT) through inhibiting the TGF-β/smads signaling pathway in CC.

Materials and methods
Ethics statement
This study coincided with the principle of voluntariness with the consent for the volunteers and their family. At the same time, patients had full understanding of the study and the ability to complete all the treatment plans, and signed the relevant informed consent.

Study subjects and specimens collection
CC tissues and corresponding paracancerous tissues were collected from 72 CC patients without other systemic tumors who were examined pathologically in the Third Affiliated Hospital of Zhengzhou University between January 2014 and January 2017. The age of patients ranged from 29 to 71 years, with an average age of 59.6 ± 6.8 years. All patients were not treated with biotherapy; radiotherapy or chemotherapy before the operation and had complete clinical data. In accordance with the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) system [19], the CC patients were classified as follows: 56 cases of squamous cell carcinoma, 16 cases of adenocarcinoma; 38 cases in stage I–II, and 34 cases in stage III–IV. Based on the treatment principle of CC, the patient were classified as follows: 44 cases with primary tumor < 4 cm, 28 cases with primary tumor ≥ 4 cm; postoperatively, 43 cases of N0–N1 lymph node metastases, 29 cases of N2–N3 lymph node metastases. All of the specimens were divided into two parts. One was cryopreserved in liquid nitrogen immediately after washing with normal saline and the other was embedded with paraffin and stored after 24 h of fixing with neutral buffered formalin (NBF).

Immunohistochemistry
The specimens were fixed in formaldehyde, embedded with paraffin, cut into 4 μm serial sections, and baked at 70 °C for 15 min, followed by dehydration with gradient ethanol. After inactivation of endogenous enzyme by H2O2, the specimens were rinsed with phosphate buffer solution (PBS) 3 times (5 min each time). The sections were incubated with normal goat serum at room temperature for 15 min, and incubated with 20–30 μL HOXC6 primary antibody overnight at 4 °C (diluted 1:50 with PBS; (ab41587; Abcam Inc., Cambridge, MA, USA). PBS was used as a substitute for the primary antibody as a negative control (NC). The sections were rinsed with PBS 3 times, and then incubated with the secondary antibody for 45 min at 37 °C. After being rinsed with PBS, the sections were developed with 3,3-diaminobenzidine...
Plasmid construction
The effectiveness of siRNA targeting different loci of different genes was distinct. According to the principle of complementarity proposed by Reynolds and Elbashir et al., siRNA sequences were designed and synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China) and listed as follows: control siRNA: UUC UCCGAACGUUGCAGCUGTDT (forward) and ACG UGACACGUUCCGAGAACGTT (reverse) and three HOXC6 siRNA sequences: HOXC6-siRNA-1: GUC CCUAUAACAUAGCGTDT (forward) and ACU AGAUGGUUAGGGACGCTDT (reverse); HOXC6-siRNA-2: CUUCUGGACUCUCGAADT (forward) and UAAGGAGUGCAAGAGADT (reverse); HOXC6-siRNA-3: CCGUAUGACUGAGAUCUADT (forward) and UAGAUCCAUAGCUCGGADT (reverse). Conventionally, the cells were transduced with pQCXIH-HA empty plasmid, pQCXIH-HA-HOXC6 retrovirus plasmid, and corresponding package plasmids (VSVG and GPZ). After 72 h, the supernatant was collected, processed by viral titer identification, sub-packed and preserved at −80 °C. The segment of short hairpin RNA (shRNA) with complementary sequence of HOXC6 was cloned into pLKO.1 lentiviral vector (Addgene Company, Cambridge, MA, USA), and confirmed by restriction enzyme XbaI and DNA sequencing analysis. The CC cells were transduced with lentiviral vector scramble shRNA and corresponding package plasmids (VSVG and dv8.2) using FuGENE6 transfection reagents (plasmid:FuGENE6=1 μg:3 μL; Promega Corp., Madison, Wisconsin, USA). After 48 h, the supernatant was collected, processed by viral titer identification, sub-packed and preserved at −80 °C. Subsequently, C3H10T1/2 cells were transduced for 12 h with pQCXIH-HA and pQCXIH-HA-HOXC6 retrovirus using 6 μg/mL polybrene (Sigma-Aldrich Chemical Company, St Louis, MO, USA). After 48 h, stable-transduced cells with pQCXIH-HA and pQCXIH-HA-HOXC6 were obtained after 200 μg/mL hygromycin screening for 7 days. Western blot analysis was used to detect the expression of HA-HOXC6 at the protein level.

Cell transduction and grouping
Cells at the logarithmic phase were seeded onto a 6-well plate and incubated in a fresh complete medium until cell confluence reached to 50–80%. Subsequently, lipofection was performed in line with the instructions of Lipofectamine 2000 (11668-027; Invitrogen Inc., Carlsbad, CA, USA). Briefly, 200 μL complex of transfection reagents and plasmids/vectors was prepared and cell transduction was carried out under serum-cultured conditions in 5% CO₂ at 37 °C for 6 h. The cells were assigned into: blank (human CC cells), NC (human CC cells + empty vector), HA-HOXC6 (human CC cells + HOXC6 overexpression vector), HOXC6-siRNA (human CC cells + HOXC6-siRNA vector), SB431542 (human CC cells + TGF-β/smab pathway antagonist), SB431542 + HOXC6-siRNA (human CC cells + TGF-β/smab pathway antagonist + HOXC6-siRNA vector), and
HA-TGF-β1 groups (the overexpressed plasmid of TGF-β1). After transduction, the cells were starved for 24 h. The experiment was repeated three times.

**Reverse transcription quantitative polymerase chain reaction (RT-qPCR)**

Total RNA was extracted from CC tissues and paracancerous tissues or cells after treatment using Trizol agent (TaKaRa Biotechnology Co., Ltd., Dalian, Liaoning China) and its purity and concentration were determined. Next, reverse transcription of RNA samples (10 μL) was conducted in order to prepare complementary DNA (cDNA) according to the instructions of reverse transcription kit (DRR047S; TaKaRa Biotechnology Co., Ltd., Dalian, Liaoning China). The obtained cDNA was diluted in 65 μL diethyl phosphorocyanidate (DEPC) and fully mixed. RT-qPCR was conducted with following reaction system: 5 μL SsoFast EvaGreen Supermix (170882; Bio-Rad, Inc., Hercules, CA, USA), 0.5 μL forward primer (10 μM), 0.5 μL reverse primer (10 μM), and 4 μL cDNA. The reaction conditions were pre-denaturation at 95 °C for 1 min, 30 cycles of denaturation at 95 °C for 30 s, annealing at 58 °C for 5 s, and extension at 72 °C for 5 s. The primers were synthesized by Shenzhen BGI Health Technology Co., Ltd. (Shenzhen, China) (Table 1). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was taken as the internal reference and genes in each sample were set for three repetitions. The reliability of PCR results was evaluated by solubility curve: \( \Delta Ct = CT_{\text{target gene}} - CT_{\text{internal reference}} \), \( \Delta \Delta Ct = \Delta Ct_{\text{experimental group}} - \Delta Ct_{\text{control group}} \). The relative expression of related genes were obtained by \( 2^{-\Delta \Delta Ct} \) [20], and the experiment was repeated three times.

**Western blot analysis**

Human CC tissues and paracancerous tissues were placed in centrifuge tubes and added with lysate in 1:8 (m/V). The tissues were intermittently homogenized by ice bath 6 times (6 s each time) and centrifuged at 27,000×g for 5 min, and the supernatant was extracted as the total protein. Total protein was divided into two parts: one part was used for determination of protein concentration; the other was added with appropriate 5× loading buffer, mixed, bathed in boiling water for 5 min, and preserved at −80 °C. Equal amounts of total protein were transferred onto polyvinylidene fluoride (PVDF) membrane after separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The membrane was washed once with tris buffered saline with Tween 20 (TBST), blocked with 5% non-fat milk powder, and shaken for 2 h. The membrane was washed three times with TBST and then incubated with primary antibodies diluted by sealing fluid, including HOXC6 (1:2000, AB151575), TGF-β1 (1:2000, ab27969), TGF-βRII (1:1000, ab61213), smad4 (1:2000, ab40759), smad7 (1:1000, ab90086), E-cadherin (1:10000, ab134175), and GAPDH (1:2500, ab9458).

**Table 1 The primer sequences for RT-qPCR**

| Name       | Sequence (5′-3′)                  |
|------------|----------------------------------|
| HOXC6      | Forward: CTCACAGGTGACTGGAAGTG    |
|            | Reverse: AGCTGCGGATAGCATCAGTC    |
| TGF-β1     | Forward: GATACGAGTAACTGCGG       |
|            | Reverse: CATTCCCTGGAGCCAGGTC     |
| TGF-βRII   | Forward: AGCAACTGCGACATCACCTC    |
|            | Reverse: TGATGCTGAGAAAGTGC       |
| smad4      | Forward: TGCTGCGATCTGGTAGATGTA   |
|            | Reverse: TAGGGCATCCATGGTAGAGAGA  |
| smad7      | Forward: TTTCCCGGCTGAAACACGG    |
|            | Reverse: CCTCCCAAGTAGCCACCAC     |
| E-cadherin | Forward: GTTTCGCTTATTGGCGGGA     |
|            | Reverse: TCTAACAAGCGCTACTGCG     |
| N-cadherin | Forward: CTGTCTGAAAAACACCGAGC    |
|            | Reverse: TTTCTGCTCCCCGCAAACA     |
| Vimentin   | Forward: GCCGCGATTGTCTGCAACAT    |
|            | Reverse: TACTCAACEAAAGAGGGCAGC   |
| GAPDH      | Forward: CACACGGTTTGTGTCACCTGA   |
|            | Reverse: CCAGATTGGGAGCAATGTCGC   |

RT-qPCR reverse transcription quantitative polymerase chain reaction, GAPDH glyceraldehyde-3-phosphate dehydrogenase, HOXC6 homeobox C6, TGF-β, transforming growth factor-β/smads signaling pathway.

**3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay**

After transduction, the cells at logarithmic growth phase were diluted into single cell suspension and cell concentration was adjusted to 2.0×10^5 cells/L. Then, the...
cell suspension was transferred into 96-well plates with 100 µL each well. Three groups were set for each cell line and three repetitions were set in each group with 5 × 10^3 cells in each well. The cells were incubated in a CO₂ incubator at 37 °C for 24 h, 48 h, 72 h and 96 h, and each well was added with 10 µL MTT solution (Sigma-Aldrich Chemical Company, St Louis, MO, USA) in the dark for incubation for 4 h. After extraction of culture supernatant, each well was added with 100 µL Dimethyl Sulphoxide (DMSO) in the dark. The plate was incubated on a flat plate oscillator for 15 min to fully dissolve the DMSO, and the optical density (OD) of each well was read at wavelength of 570 nm in a Microplate Reader (BioTek, Winooski, VT, USA). Cell viability curve was drawn with time as X-axis and OD value as Y-axis. The experiment was repeated three times.

**Propidium iodide (PI) staining**

After 48-h transduction, cells at logarithmic growth phase were collected to prepare 5 × 10^6 cells/L of single cell suspension. The cells were rinsed with PBS, resuspended in 70% ethanol and PBS containing 0.5 mmol/L LEDTANa₂, and fixed at 4 °C for 1 h. Subsequently, the cells were centrifuged at 300 × g, suspended with mixture of 0.01% Triton X-100 and 50 g/L PBS, transferred into a testing tube, and then stained with 0.5 g/L PI dye liquor for 30 min in the dark. Flow cytometer (Coulter Corporation, San Diego, California, USA) was used for cell counting, and the percentage of cells in each phase was observed. The experiment was repeated three times.

**Annexin V-FITC/PI double staining**

At 48 h after transduction, the cells in each group were treated with ethylene diamine tetraacetic acid (EDTA)-free trypsin and placed in flow tubes (a few dead cells and apoptotic cells were included in the supernatant and all of them were involved in the statistics), followed by centrifugation at 100 × g for 5 min. After discarding the supernatant, the cells were washed with cold PBS 3 times, with the supernatant removed. According to the protocol of Annexin-V-FITC kit (Sigma-Aldrich Chemical Company, St Louis, MO, USA), each tube was added 150 µL binding buffer and 5 µL Annexin V-FITC, mixed gently, and incubated at room temperature for 15 min in the dark. Each tube was added with 100 µL binding buffer and 5 µL PI (Sigma, Saint Louis, Missouri, USA), and mixed. The control group was not added with Annexin V as a correction factor. Cell apoptosis was detected within 1 h by flow cytometry (Coulter Corporation, San Diego, California, USA). The results were shown by a four lattice graph with right upper limit as the proportion of advanced apoptotic cells, right lower limit as the proportion of early apoptotic cells, left upper limit as the proportion of dead cells, left lower limit as the proportion of living cells. The experiment was repeated three times.

**Statistical analysis**

All data was analyzed using SPSS Version 22.0 software (IBM Corporation, San Diego, CA, USA). The measurement data with normal distribution was exhibited as the mean ± standard deviation (SD). Comparison between CC tissues and paracancerous tissues was conducted using paired t-test and pairwise comparison between the other groups using student’s t-test. The comparisons among multiple groups were conducted by the one-way analysis of variance (ANOVA) for variance analysis and significance test. The data at different time points were compared using repeated-measurement ANOVA. Pearson correlation analysis was used to analyze the linear interaction of HOXC6 mRNA to TGF-β1, TGF-β RI, smad4, and smad7 mRNA. The enumeration data were represented as percentage and analyzed by chi-square test. p < 0.05 was considered to be of statistically significance.

**Results**

**HOXC6 is upregulated and the TGF-β/smado4 signaling pathway is activated in CC**

Immunohistochemistry was used to determine positive expression rate of HOXC6 to analyze the function of HOXC6 in CC. As shown in Fig. 1a, b, HOXC6 protein was expressed in the cytoplasm, and positive cells displayed granules in light yellow to tan, which scattered or clustered together in cytoplasm. The results of immunohistochemistry showed that: the HOXC6 protein was found in 44 CC tissue samples, with the positive rate of 61.1% and the staining intensity of 3 points; the HOXC6 protein was found in 13 paracancerous tissue samples, with the positive rate of 18.1% and the staining intensity of 1 point. The positive expression rate of HOXC6 protein in CC tissues was significantly higher than that in paracancerous tissues (p < 0.05). Results of RT-qPCR, which was performed to detect the mRNA expression of HOXC6, TGF-β1, TGF-β RI, smad4, and smad7, suggested that when compared to the paracancerous tissues, the CC tissues presented upregulated mRNA expression of HOXC6, TGF-β1, TGF-β RI, smad4, and smad7, but downregulated that of smad7 (all p < 0.05; Fig. 1c). The linear interaction of HOXC6 to TGF-β1, TGF-β RI, and smad4 was analyzed using Pearson correlation analysis, finding that HOXC6 was positively correlated to TGF-β1, TGF-β RI, and smad4 but negatively correlated to smad7 (all p < 0.05; Fig. 1d). Thus, CC tissues exhibit elevated HOXC6 expression and the activated TGF-β/smado4 signaling pathway
and HOXC6 expression is positively correlated to the TGF-β/smads signaling pathway.

**Expression of HOXC6 is associated with the severity of the development of CC**

Subsequently, the association between HOXC6 protein and clinicopathological characteristics in CC patients was analyzed in this study. The results revealed that HOXC6 protein expression was related to TNM stage, lymphatic metastasis, cancer types, primary lesion diameter and histological grade (all \( p < 0.05 \)), but had no correlation with age (\( p > 0.05 \)) (Table 2). Therefore, HOXC6 expression is associated with severity of the development of CC.

**Higher HOXC6 expression is found in HeLa and SiHa cell lines**

To explore which cell line is more suitable for our experiment, RT-qPCR and western blot analysis were performed to measure HOXC6 expression in C-33A, HeLa, CaSki, SiHa, ME-180 and HCC-94 cell lines. The results (Fig. 2a–c) showed that: Hela cells showed the highest HOXC6 mRNA expression followed by SiHa cells, and the rest cell lines had no significant difference in HOXC6 expression.

| Table 2 Relationship between HOXC6 protein and clinicopathological characteristics in CC patients |
|-----------------|-----------------|----------|----------|
| Influence factors | Cases | HOXC6 | \( p \) value |
| -----------------|-------|-------|-------------|
| Age (years) | | | 0.427 |
| < 55 | 51 | 33 | 18 |
| \( \geq 55 \) | 21 | 11 | 10 |
| TNM stage | | | 0.016 |
| I–II | 38 | 18 | 20 |
| III–IV | 34 | 26 | 8 |
| Lymphatic metastasis | | | 0.001 |
| N0–N1 | 43 | 19 | 24 |
| N2–N3 | 29 | 25 | 4 |
| Cancer type | | | 0.019 |
| Squamous cell carcinoma | 56 | 30 | 26 |
| Sdenocarcinoma | 16 | 14 | 2 |
| Primary lesion diameter (cm) | | | 0.006 |
| < 4 | 44 | 21 | 23 |
| \( \geq 4 \) | 28 | 23 | 5 |
| Histological grade | | | 0.016 |
| G1–G2 | 41 | 20 | 21 |
| G3 | 31 | 24 | 7 |

CC cervical carcinoma, HOXC6 homeobox C6. Chi-square test was used for statistical analysis.
mRNA expression. Furthermore, the results of western blot analysis were consistent with HOXC6 mRNA expression in six kinds of human CC cells. Due to higher expression of HOXC6 in HeLa and SiHa cell lines, these two cell lines were chose for the subsequent experiments. Since the effectiveness of siRNA targeting different loci of different genes was distinct, this study designed three different siRNA sequences to analyze their interference efficiency, finding that HOXC6-siRNA-3 had the best interference efficiency and was selected for subsequent experiments (Fig. 2d).

**HOXC6 gene silencing inhibits the activation of TGF-β1/smads signaling pathway in CC cells**

To explore the effect of HOXC6 on the TGF-β1/smads signaling pathway, the mRNA and protein expression of HOXC6, TGF-β1, TGF-β RII, smad4 and smad7 were determined by RT-qPCR and western blot analysis. As shown in Fig. 3a–f, compared with the blank group, expression of HOXC6, TGF-β1, TGF-β RII, and smad4 were significantly decreased but smad7 was markedly increased in the HOXC6-siRNA, SB431542 and SB431542 + HOXC6-siRNA groups, which was opposite with the tendency in the HA-HOXC6 group (all p < 0.05). Compared with the HOXC6-siRNA and SB431542 groups, the SB431542 + HOXC6-siRNA group showed significantly decreased mRNA and protein expression of HOXC6, TGF-β1, TGF-β RII, and smad4 (all p > 0.05). There was no significant difference in expression of HOXC6, TGF-β1, TGF-β RII, smad4 and smad7 between the NC and blank groups, or between the HOXC6-siRNA and SB431542 groups (all p > 0.05). In SiHa cells, expression of HOXC6, TGF-β1, TGF-β RII, smad4 and smad7 were identical to that in HeLa cells, but the expression of those genes were weaker than that in HeLa cells. It indicated that HOXC6 siRNA could suppress the activation of TGF-β1/smads signaling pathway in CC cells.

**HOXC6 gene silencing inhibits EMT in CC cells**

Twenty-four hours after transduction with HOXC6-siRNA in HeLa and SiHa cell lines, RT-qPCR and western blot analysis were used to determine the mRNA and protein expression of E-cadherin, N-cadherin and Vimentin to investigate how HOXC6 affected EMT in CC cells. Compared with the blank group, the expression of N-cadherin and Vimentin were remarkably increased in the HA-HOXC6 group, while decreased in the HOXC6-siRNA, SB431542, and SB431542 + HOXC6-siRNA groups; E-cadherin expression was notably decreased in the HA-HOXC6 group, while increased in the HOXC6-siRNA, SB431542, and SB431542 + HOXC6-siRNA groups (all p < 0.05). The change of each index in the HOXC6-siRNA group was contrary to that in the HA-HOXC6 group (p < 0.05). In comparison to the HOXC6-siRNA and SB431542 groups, the SB431542 + HOXC6-siRNA group showed a significant decrease in the expression of N-cadherin and Vimentin and a significant increase in E-cadherin expression (all p < 0.05) (Fig. 4a–f). These findings demonstrated that HOXC6 siRNA could upregulate E-cadherin expression and downregulate N-cadherin and Vimentin expression in HeLa and SiHa cells.

**HOXC6 gene silencing inhibits cell proliferation in CC cells**

To explore the effect of HOXC6 on cell proliferation, MTT assay was performed to detect cell viability in HeLa and SiHa cells. The cell viability in each group showed an upward trend at every time point, and kept consistent in HeLa and SiHa cell lines. Compared with the blank group, cell proliferation was significantly promoted in the HA-HOXC6 group, while suppressed in the HOXC6-siRNA, SB431542, and SB431542 + HOXC6-siRNA groups at each time point after 48 h of transduction (all p < 0.05). In comparison to the HOXC6-siRNA and SB431542 groups, the SB431542 + HOXC6-siRNA group
showed an inhibition of cell proliferation ($p < 0.05$). There was no significant difference in cell viability in HeLa and SiHa cells between the NC and blank groups or between the HOXC6-siRNA and SB431542 groups (all $p > 0.05$). The relative protein expression of Ki67 and PCNA in each cell line was determined using western blot analysis, showing that in contrast to the NC and blank groups, the relative protein expression of Ki67 and PCNA was overexpressed in the HA-HOXC6 group but decreased in the HOXC6-siRNA, SB431542, and SB431542 + HOXC6-siRNA group (Fig. 5a–c). These results suggested that HOXC6 siRNA had inhibitory effect on the proliferation in HeLa and SiHa cells.

**HOXC6 gene silencing inhibits cell cycle progression of CC cells**

To explore how HOXC6 affect cell proliferation, PI staining was carried out to detect the cell cycle distribution in HeLa and SiHa cells after transduction. The cell cycle in each group showed consistent trend in HeLa and SiHa cell lines (Fig. 6a–d). Compared with the blank group, the HOXC6-siRNA and SB431542 groups showed higher percentage of cells at G0/G1 phase and lower percentage of cells at S phase (all $p < 0.05$). In comparison to the blank and NC groups, the HA-HOXC6 group showed lower percentage of cells at G0/G1 phase and higher percentage of cells at S phase,
while the SB431542 + HOXC6-siRNA group showed higher percentage of cells at G0/G1 phase and lower percentage of cells at S phase ($p < 0.05$). There were no significant differences of cell cycle distribution between the NC and blank groups, as well as the HOXC6-siRNA and SB431542 groups ($p > 0.05$). Western blot analysis was carried out to detect the relative protein expression of p27 and cyclin D1 in each cell line. The results (Fig. 6e) revealed that in comparison with the blank and NC groups, the protein expression of p27 was elevated in the HA-HOXC6 group, but reduced in the HOXC6-siRNA, SB431542, and SB431542 + HOXC6-siRNA groups. The protein expression of cyclin D1 was opposite to that of p27. These results suggested that downregulation of HOXC6 could significantly inhibit the proliferation in HeLa and SiHa cells.

**HOXC6 gene silencing promotes cell apoptosis in CC cells**

Cell apoptosis was tested by flow cytometry. In comparison to the blank group, cell apoptosis rate was significantly decreased in the HA-HOXC6 group and increased in the HOXC6-siRNA, SB431542, and SB431542 + HOXC6-siRNA groups (all $p < 0.05$). There was no statistical significance between the NC and blank groups, as well as the HOXC6-siRNA and SB431542 groups ($p > 0.05$) (Fig. 7). The above findings indicated that HOXC6 gene silencing could induce cell apoptosis of CC cells.
HOXC6 silencing represses EMT and proliferative ability of CC cells via inhibiting the activation of the TGF-β/smadi signaling pathway

Based on HOXC6-siRNA, rescue assay was performed with the HA-TGF-β1 group (the overexpressed TGF-β1 plasmid) added. It was found that HOXC6-siRNA could inhibit EMT and proliferative ability of CC. After the treatment of HA-TGF-β1, EMT and proliferative ability of CC were rescued and the protein expression of the signaling pathway was also elevated, suggesting that HOXC6 worked via the TGF-β/smadi signaling pathway. The HA-HOXC6 group presented enhanced EMT and proliferative ability of CC, which were diminished with the addition of si-TGF-β1 (Fig. 8a–d). These results provide evidence that HOXC6 gene silencing could inhibit the TGF-β/smadi signaling pathway, thus suppressing EMT and proliferative ability of CC cells.

Discussion

CC is the fourth commonest cancer in female worldwide [21]. Moreover, molecular mechanisms of CC remain poor understanding [22]. Furthermore, HOXC6 is involved in various cancers including lung cancer, osteosarcomas and breast cancer [10]. Therefore, in the current study, we focused on HOXC6 gene in regulation of CC progression with the involvement of TGF-β/smadi signaling pathway, and our results demonstrate that HOXC6 gene silencing can suppress the EMT and cell viability in CC through inactivating the TGF-β/smadi signaling pathway.

Initially, elevated mRNA and protein expression of HOXC6 were found in CC. HOXC6 gene is one of the homeoprotein transcription factors, which mainly regulate embryonic development and play roles in several cellular processes such as differentiation and
Fig. 6  HOXC6 gene silencing arrests cells in G0/G1 phase in CC cells. a Cell cycle of each group in HeLa cells; b cell cycle of each group in SiHa cells; c cell cycle distribution in HeLa cells; d cell cycle distribution in SiHa cells; e relative protein expression of p27 and cyclin D1 in each cell line determined by western blot analysis; *p < 0.05 compared with the blank group; †p < 0.05, compared with the NC group; ‡p < 0.05, compared with the SB431542 group; NC negative control, PI propidium iodide, HOXC6, homeobox C6
morphogenesis [23]. Supportively, evidence has demonstrated that HOXC6 gene has association with various tumor progressions. For instance, overexpressed HOXC6 is frequently observed in prostate cancers and relates to adverse clinical parameters [24]. Overexpressed HOXC6 is closely linked to poor survival of patients with gastric cancer, and contributes to gastric carcinogenesis progression [25]. A previous study highlighted overexpression f HOXC6 in tumor tissues of colorectal cancer [26]. It has been reported that there are correlations of HOXC6 overexpression with increment of tumor stage, advanced nodal status in nasopharyngeal carcinoma [27].

Furthermore, the HOXC6-siRNA group witnessed a notable decline in the mRNA and protein expression of HOXC6, TGF-β1, TGF-β RII, smad4, smad7, N-cadherin and Vimentin, but an increase in E-cadherin expression. The TGF-β/smad signaling pathway can be initiated by TGF-β1 binding to TGF-β RII, and smads are essential for the transduction of TGF-β1-mediated signals.

**Fig. 7** HOXC6 gene silencing promotes cell apoptosis in CC cells. 

- **a** HeLa cell apoptosis after transduction; 
- **b** apoptosis rate of HeLa cells after transduction; 
- **c** SiHa cell apoptosis after transduction; 
- **d** apoptosis rate of SiHa cells after transduction; 

* *p < 0.05 compared with the blank group; 
†p < 0.05, compared with the NC group; 
&& p < 0.05, compared with the SB431542 group; 
NC negative control, HOXC6 homeobox C6
inactivating the TGF-β/smad signaling pathway.

Can be seen that HOXC6 gene silencing inhibit the EMT regulator of cell apoptosis and proliferation of U251 cells [33, 36]. Based on these findings, it can be seen that HOXC6 gene silencing inhibit the EMT in CC by inactivating the TGF-β/smad signaling pathway.

Additionally, our study demonstrated that HOXC6 gene silencing inhibits cell proliferation and promotes cell apoptosis in CC cells. HOXC6 overexpression is capable of promoting colony formation and upregulating tumor growth factors, suggesting its important role in tumor growth [10]. It has revealed that HOXC6 overexpression induced colony formation and cell proliferation in gastric cancer [37]. Overexpressed HOXC6 is found in human head and neck squamous cell carcinoma cell lines and promote proliferation [38]. Consistently with our results, knockout of HOXC6 inhibited cell migration and proliferation in hepatocellular carcinoma [39]. HOXC6 gene silencing enables prostate cancer cell to apoptosis [40]. TGF-β family participated in the modulation of cell differentiation, proliferation, apoptosis, and motility, and TGF-β-induced growth inhibition was found to be repressed in tumor cells [41]. Previous research suggested that TGF-β/smad2/3 signaling pathway is a crucial regulator of cell apoptosis and proliferation of U251 cells [42]. What's more, DKK3 overexpression suppressed collagen synthesis, induced cell apoptosis, and inhibited cell proliferation via TGF-β1/smad pathway in keloid fibroblasts [43]. These evidences support that HOXC6 gene silencing inhibited cell proliferation and promoted cell apoptosis in CC cells by inactivating the TGF-β/smad signaling pathway.

Conclusion
Collectively, the key finding from this study is that HOXC6 gene can act as a regulator of CC cell viability. Suppression of HOXC6 gene results in suppressed cell proliferation, promoted cellular apoptosis and weakened abilities of EMT through blocking the activation of the TGF-β/smad signaling pathway. Our finding demonstrates the pivotal role of HOXC6 gene in CC advancement and suggests that it could serve as a therapeutic target in CC management, and further larger-scale studies and in vivo experiments are needed to validate this clinical utility.

Abbreviations
HOXC6: Homeobox C6; CC: cervical carcinoma; EMT: epithelial-mesenchymal transition; TGF-β: transforming growth factor-β; AJCC: American Joint Committee on Cancer; TNM: tumor-node-metastasis; NBF: neutral buffered formalin; PBS: phosphate buffer solution; NC: negative control; DAB: diaminobenzidine; FBS: fetal bovine serum; DEPC: diethyl phosphorocyanidate; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; PVDF: polyvinylidene fluoride; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; TBST: tris buffered saline with Tween 20; HRP: horse radish peroxidase; ECL: enhanced chemiluminescence; DMSO: dimethyl sulphoxide; OD: optical density; PI: propidium iodide; EDTA: ethylene diamine tetraacetic acid.

Authors' contributions
FZ and CCR provided the conception and design the study. LL performed the experiments. YNC and LY analyzed data. XAZ wrote the main manuscript text. All authors read and approved the final manuscript.

Acknowledgements
The authors are grateful to reviewers for critical comments to the manuscript.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication
Consent for publication was obtained from the participants.
Ethics approval and consent to participate

This study coincided with the principle of voluntariness with the consent for the volunteers and their family. At the same time, patients had full understanding of the study and the ability to complete all the treatment plans, and signed the relevant informed consent.

Funding

This work was supported by Science and Technology Department of Henan (China) (Grant No.161100311100, No.172102310168 and No.162102310131). National Health and Family Planning Commission of Henan (China) (Grant No.201601010).

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 29 June 2018 Accepted: 6 November 2018 Published online: 12 December 2018

References

1. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86.
2. Ondrusova M, Zubor P, Onduš D. Time trends in cervical cancer epidemiology in the Slovak Republic: reflection on the non-implementation of screening with international comparisons. Neoplasma. 2012;59(2):121–8.
3. Mwaka AD, Orach CG, Were EM, Lyratopoulos G, Wabinga H, Roland M. Awareness of cervical cancer risk factors and symptoms: cross-sectional community survey in post-conflict northern Uganda. Health Expect. 2016;19(4):854–67.
4. Masch R, Ditzian LR, April AK, Maza M, Peralta E, Cremer ML. Cervical cancer screening and treatment training course in El Salvador: experience and lessons learned. J Womens Health (Larchmt). 2011;20(9):1357–61.
5. Ma SR, Mao L, Deng WW, Li YC, Bu LL, Yu GT, Zhang WF, Sun ZJ. AGR2 homeobox gene expression in cervical carcinoma. Int J Gynecol Cancer. 2006;16(1):329–35.
6. Agnelli L, Storti P, Todoerti K, Sammarelli G, Dalla Palma B, Bolzoni M, Rocci A, Piazza F, Semenzato G, Palumbo A, Neri A, Giuliani N. Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations. Am J Hematol. 2011;86(12):646–4.
7. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Immunocytochemical detection of the homeobox B3, B4, and C6 gene product in childhood medulloblastomas/primitive neuroectodermal tumors. Anticancer Res. 2000;20(3A):1769–80.
8. Bodey B, Bodey B Jr, Siegel SE, Luck JV, Kaiser HE. Homeobox box B3, B4, and C6 gene product expression in osteosarcomas as detected by immunocytochemistry. Anticancer Res. 2002;20(4):2717–21.
9. Hussain I, Bhan A, Ansari KI, Deb P, Bobzean S, Perrotti LL, Mandall SS. Bisphenol-A induces expression of HOXC6, an estrogen-regulated homeobox-containing gene associated with breast cancer. Biochim Biophys Acta. 2015;1846(9):697–708.
10. Bodey B, Bodey B Jr, Groger AM, Siegel SE, Kaiser HE. Immunocytochemical detection of homeobox B3, B4, and C6 gene product expression in lung carcinomas. Anticancer Res. 2000;20(4):2711–6.
11. Moreno CS. The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways. Am J Pathol. 2010;176(2):518–27.
12. Hamid AR, Hoogland AM, Smit F, Jannink S, van Rijt-van de Westerlo C, Jansen CE, van Leenders GJ, Verhaagh GW, Schalken JA. The role of HOXC6 in prostate cancer development. Prostate. 2015;75(16):1868–76.
13. Zhou B, Chen L, Wu X, Wang J, Yin Y, Zhu G. MH1 domain of SMAD4 binds N-terminal residues of the homeodomain of Hoxc9. Biochim Biophys Acta. 2008;1784(5):747–52.
14. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol Cell. 2010;39(3):373–84.
15. Pang K, Ryan JF, Baxevanis AD, Marintrade MQ. Evolution of the TGF-beta signaling pathway and its potential role in the ctenophore, Mnemiopsis leidyi. PloS ONE. 2011;6(9):e24152.
16. Slattery ML, Herrick JS, Lundgreen A, Wolff RK. Genetic variation in the TGF-beta signaling pathway and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2011;20(1):57–69.
17. Zhang XM, Luo J. Long noncoding RNA UCA1 modulates breast cancer cell growth and apoptosis through decreasing tumor suppressive miR-143. Eur Rev Med Pharmacol Sci. 2015;19(18):3403–11.
18. Wang CH, Zhou Z, Li H, Wu X, Yang M, Lou C, Li J, Cai Y, Li P, Jiang JB. The expression of HOX genes and its relation to pathological stage in cervical cancer patients undergoing radical hysterectomy. Mol Cell. 2015;60(4):262–9.
19. Ge TT, Yang M, Chen Z, Lou G, Gu T. HUHRF1 gene silencing inhibits cell proliferation and promotes cell apoptosis in human cervical squamous cell carcinoma Ca5i cells. J Ovarian Res. 2016;9(1):42.
20. Tao YL, Li XM, Luo J. Long noncoding RNA UCA1 regulates breast cancer cell growth and apoptosis through decreasing tumor suppressive miR-143. Eur Rev Med Pharmacol Sci. 2015;19(18):3403–11.
21. Nathamongkolkul K, Hanprasertpong J. Longer waiting times for early stage cervical cancer patients undergoing radical hysterectomy are associated with diminished long-term overall survival. J Gynecol Oncol. 2015;26(4):262–9.
22. Ge TT, Yang M, Chen Z, Lou G, Gu T. HUHRF1 gene silencing inhibits cell proliferation and promotes cell apoptosis in human cervical squamous cell carcinoma Ca5i cells. J Ovarian Res. 2016;9(1):42.
23. Tucci R, Campos MS, Matzonzkas-Antonio LF, Durazzo M, Junior P, dos Santos D, Nunes FD. HOX8 expression in oral squamous cell carcinoma. J Appl Oral Sci. 2011;19(2):125–9.
24. Vinarskaja A, Yamana K, Ingemarson M, Schulz WA. DNA methylation and the HOXC6 paradox in prostate cancer. Cancers (Basel). 2011;3(4):3714–25.
25. Zhang Q, Jin XS, Yang Z, Wei M, Liu BY, Gu QL. Upregulated HOXc6 expression is associated with poor survival in gastric cancer patients. Neoplasma. 2013;60(4):349–55.
26. Ji M, Feng Q, He G, Yang L, Tong W, Lao X, Zhu D, Lin Q, Xu P, Wei Y, Xu J. Silencing homeobox C6 inhibits colorectal cancer cell proliferation. Oncotarget. 2016;7(20):29216–27.
27. Chang SL, Chan TC, Chen TJ, Lee SW, Lin LC, Win KT. HOX6 overexpression is associated with Ki-67 expression and poor survival in NPC patients. J Cancer. 2017;8(9):1647–54.
28. Liu B, Zhao YN, Li Q, Li Q, Wu Q, Zhang ZY, Ji R, Guo QH, Liu W. Correlations of TGF-betaRII, Smad4 and Smad7 expression to clinicopathologic characteristics and prognosis of gastric cancer. Ai Zheng. 2009;28(5):538–42.
29. Nunes FDA, Tucci R. Genes homeobox: uma relação molecular entre o desenvolvimento e o câncer[J]. Pesquisa Odontológica Brasileira. 2003(171):94–8.
30. Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, Kawaguchi Y, Fujimoto K, Hosotani R, Imamura M. N-cadherin expression and epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–96.
31. Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. J Appl Oral Sci. 2003;11(2):94–8.
32. Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. J Appl Oral Sci. 2003;11(2):94–8.
33. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
34. Devine DJ, Rostas JW, Metge BJ, Das S, Mulekar MS, Tucker JA, Grizzle WE, Buchsbaum DJ, Shvede LA, Samant RS. Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-beta/SMAD signaling pathway in cervical cancer. Oncol Rep. 2014;33(20):2620–8.
35. Xiao W, Zhou S, Xu H, Li H, He G, Liu Y, Qi Y. Nogo-B promotes the epithelial-mesenchymal transition in Hela cervical cancer cells via Fibulin-5. Oncol Rep. 2013;29(1):109–16.
36. Derynck R, Muthusamy BP, Saeteurn KY. Signaling pathway cooperation in TGF-beta-induced epithelial-mesenchymal transition. Curr Opin Cell Biol. 2014;31:56–66.

37. Chen SW, Zhang Q, Xu ZF, Wang HP, Shi Y, Xu F, Zhang WJ, Wang P, Li Y. HOXC6 promotes gastric cancer cell invasion by upregulating the expression of MMP9. Mol Med Rep. 2016;14(4):3261–8.

38. Moon SM, Kim SA, Yoon JH, Ahn SG. HOXC6 is deregulated in human head and neck squamous cell carcinoma and modulates Bcl-2 expression. J Biol Chem. 2012;287(42):35678–88.

39. Sui CJ, Xu F, Shen WF, Dai BH, Lu JJ, Zhang MF, Yang JM. MicroRNA-147 suppresses human hepatocellular carcinoma proliferation migration and chemosensitivity by inhibiting HOXC6. Am J Cancer Res. 2016;6(12):2787–98.

40. Ramachandran S, Liu P, Young AN, Yin-Goen Q, Lim SD, Laycock N, Amin MB, Carney JK, Marshall FF, Petros JA, Moreno CS. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene. 2005;24(1):186–98.

41. Gulubova M, Manolova I, Ananiev J, Julianov A, Yovchev Y, Peeva K. Role of TGF-beta1, its receptor TGFbetaRII, and Smad proteins in the progression of colorectal cancer. Int J Colorectal Dis. 2010;25(5):591–9.

42. Zhao HW, Li YW, Feng R, Yu JB, Li J, Zhang Y, Li JC, Wang YX. TGF-beta/Smad2/3 signal pathway involves in U251 cell proliferation and apoptosis. Gene. 2015;562(1):76–82.

43. Li Y, Liu H, Liang Y, Peng P, Ma X, Zhang X. DKK3 regulates cell proliferation, apoptosis and collagen synthesis in keloid fibroblasts via TGF-beta1/Smad signaling pathway. Biomed Pharmacother. 2017;91:174–80.